magrolimab
magrolimab: developed by 1 company · 3 clinical trials tracked.
magrolimab evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could magrolimab → FTSV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Forty Seven, Inc. (FTSV) MDS and AML | Phase 1 |
Clinical Trials (3)
A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Primary endpoint: Complete Response (CR)
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Primary endpoint: Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Primary endpoint: Stage 1 mUC Cohorts: Objective Response Rate (ORR)
Frequently asked questions
Who is developing magrolimab?
magrolimab is being developed by Forty Seven, Inc..
How many clinical trials involve magrolimab?
BioSniper tracks 3 clinical trials involving magrolimab.